CP-615003 is a drug which acts as a subtype-selective partial agonist at GABAA receptors and was developed by Pfizer as a potential anxiolytic however poor blood–brain barrier penetration make it primarily useful as a research ligand.
This page contains content from the copyrighted Wikipedia article "CP-615003"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
